What’s in a name?
Well, if it’s the same name as a treatment with nearly $1 billion in sales per year in the U.S., a retraction.
A “mind numbingly boring one,” that is.
Here’s the Twin Research and Human Genetics notice for “EpiPen: An R Package to Investigate Two-Locus Epistatic Models”: Continue reading Drug company lawyer letter results in “utterly tedious” retraction